Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Max Planck Institute for Human Development | OTHER |
| German Research Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Gynecologists frequently overestimate the benefits and safety of ovarian cancer screening. AI-supported discussions may help correct these misperceptions. This study tests whether an AI-guided conversation about the evidence on ovarian cancer screening can improve gynecologists' knowledge and reduce non-evidence-based screening recommendations, compared with a control AI discussion on ovarian cancer prevalence.
Previous research has demonstrated that gynecologists often substantially overestimate both the effectiveness and safety of ovarian cancer screening, despite robust evidence indicating that such screening does not offer a net clinical benefit. These findings highlight the need for innovative communication strategies to support evidence-based clinical practice and reduce low value care.
AI-based conversational interventions have shown promising results in other fields when aiming to correct misconceptions or encourage engagement with evidence, particularly among individuals who are initially resistant to factual information. Leveraging these insights, this study investigates whether AI-facilitated discussions can effectively improve gynecologists' knowledge of the benefit-harm profile of ovarian cancer screening and subsequently reduce non-evidence-based recommendations.
The study employs a cross-sectional study design in which gynecologists who have previously indicated to regularly recommend ovarian cancer screening with transvaginal ultrasound and potentially with additional CA 125-testing to their asymptomatic, average-risk patients are randomized to one of two conditions:
Before and after the AI-based discussion, all participants are queried on their numerical (X out of 1,000 women) and subjective perception of ovarian cancer screening's benefits and harms and their screening recommendations. Measures are derived from instruments used in prior research.
The primary objective of this study is to assess the change, from before to after the AI-based conversation, in clinicians' understanding of the benefit-harm ratio and their recommendations regarding routine ovarian cancer screening for asymptomatic, average-risk women, within and between study groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control (ChatGPT Control Condition) | Other | Participants in this arm engage in a three-turn conversation with ChatGPT. The AI's role is to:
|
|
| Experimental (ChatGPT Evidence-Based Screening Discussion) | Experimental | Participants in this arm engage in a three-turn conversation with ChatGPT. The AI's role is to:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ChatGPT - Control | Behavioral | Three-turn conversation; discusses ovarian cancer risk and epidemiology; avoids screening topics; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in intention to recommend ovarian cancer screening | Difference in participants' self-reported frequency of recommending ovarian cancer screening to average-risk women in the future after the ChatGPT interaction and their self-reported frequency of recommending the screening in the past. | Immediately post intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Change in benefit-harm ratio evaluation of ovarian cancer screenings | Difference between the self-reported benefit-harm ratio evaluation before and after the ChatGPT interaction. | Immediately post intervention |
| Accuracy of knowledge regarding ovarian cancer screening evidence |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Odette Wegwarth, Prof. Dr. | Contact | +49 30 450 531 074 | odette.wegwarth@charite.de | |
| Miriam K Rumpel, M.Sc. | Contact | +49 30 450 531 058 | miriam.rumpel@charite.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Charité - Universitätsmedizin Berlin | Mitte | State of Berlin | 10117 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30464251 | Background | Wegwarth O, Gigerenzer G. US gynecologists' estimates and beliefs regarding ovarian cancer screening's effectiveness 5 years after release of the PLCO evidence. Sci Rep. 2018 Nov 21;8(1):17181. doi: 10.1038/s41598-018-35585-z. | |
| 31704891 | Background | Wegwarth O, Pashayan N. When evidence says no: gynaecologists' reasons for (not) recommending ineffective ovarian cancer screening. BMJ Qual Saf. 2020 Jun;29(6):521-524. doi: 10.1136/bmjqs-2019-009854. Epub 2019 Nov 8. No abstract available. |
Not provided
Not provided
We will use osf.io to publish the raw behavioral data of the participants without any identifiers and open text communications after study completion and publishing of results (October 2026).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ChatGPT - Evidence-Based Screening Discussion | Behavioral | Three-turn conversation; asks participants about screening rationale; provides evidence-based info on benefits/harms, trial data, guideline positions; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT. |
|
Participants' understanding of benefits, harms, and guideline recommendations for ovarian cancer screening, assessed via survey questions |
| Immediately post intervention |
| 29450531 | Background | US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Feb 13;319(6):588-594. doi: 10.1001/jama.2017.21926. |